REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present at the following upcoming investor conferences:
Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
Thursday, February 8, 2024, at 2:30 PM Eastern Time
34th Annual Oppenheimer Healthcare Life Sciences Conference
Wednesday, February 14, 2024, at 11:20 AM Eastern Time
Anish Bhatnagar, M.D., Chief Executive Officer, will also be participating in a fireside chat, hosted by Dr. Leland Gershell.
A live audio webcast and replays of the presentations will be available in the Investors section on the Company’s website at www.soleno.life.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of PWS, recently completed its Phase 3 development program to support a planned NDA submission. For more information, please visit www.soleno.life.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
| Last Trade: | US$85.52 |
| Daily Change: | 1.93 2.31 |
| Daily Volume: | 1,498,016 |
| Market Cap: | US$4.510B |
July 10, 2025 July 01, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
